Cargando…

AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro

Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary. While clinical guidelines recommend all approved anticonvulsants, so far it is still unclear which of the available drugs is the best therapeutic option for treating glioma-associated seiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange, Falko, Weßlau, Konrad, Porath, Katrin, Hörnschemeyer, Julia, Bergner, Carina, Krause, Bernd Joachim, Mullins, Christina Susanne, Linnebacher, Michael, Köhling, Rüdiger, Kirschstein, Timo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361447/
https://www.ncbi.nlm.nih.gov/pubmed/30716120
http://dx.doi.org/10.1371/journal.pone.0211644
_version_ 1783392687617998848
author Lange, Falko
Weßlau, Konrad
Porath, Katrin
Hörnschemeyer, Julia
Bergner, Carina
Krause, Bernd Joachim
Mullins, Christina Susanne
Linnebacher, Michael
Köhling, Rüdiger
Kirschstein, Timo
author_facet Lange, Falko
Weßlau, Konrad
Porath, Katrin
Hörnschemeyer, Julia
Bergner, Carina
Krause, Bernd Joachim
Mullins, Christina Susanne
Linnebacher, Michael
Köhling, Rüdiger
Kirschstein, Timo
author_sort Lange, Falko
collection PubMed
description Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary. While clinical guidelines recommend all approved anticonvulsants, so far it is still unclear which of the available drugs is the best therapeutic option for treating glioma-associated seizures, also in view of possible anti-tumorigenic effects. In our study, we employed four patient-derived low-passage cell lines of glioblastoma and three cell lines of brain metastases, and challenged these cultures with four anticonvulsants with different mechanisms of action: levetiracetam, valproic acid, carbamazepine and perampanel. Cell proliferation was determined by bromodeoxyuridine incorporation. To further analyze the effects of perampanel, apoptosis induction was measured by caspase 3/7 activation. Glutamate release was quantified and glucose uptake was determined using (18)F-fluorodeoxyglucose. Real-time polymerase chain reaction was employed to assess the expression of genes associated with glutamate release and uptake in brain tumor cells. Of the four anticonvulsants, only perampanel showed systematic inhibitory effects on cell proliferation, whereas all other anticonvulsants failed to inhibit glioma and metastasis cell growth in vitro. Metastasis cells were much more resistant to perampanel than glioblastoma cell lines. Glucose uptake was attenuated in all glioblastoma cells after perampanel exposure, whereas cell death via apoptosis was not induced. Extracellular glutamate levels were found to be significantly higher in glioblastoma cell lines as compared to metastasis cell lines, but could be reduced by perampanel exposure. Incubation with perampanel up-regulated glutamine synthetase expression in glioblastoma cells, whereas treatment with valproic acid and levetiracetam downregulated excitatory amino acid transporter-2 expression. Overall, our data suggest that perampanel acts as an anticonvulsive drug and additionally mediated anti-tumorigenic effects.
format Online
Article
Text
id pubmed-6361447
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63614472019-02-15 AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro Lange, Falko Weßlau, Konrad Porath, Katrin Hörnschemeyer, Julia Bergner, Carina Krause, Bernd Joachim Mullins, Christina Susanne Linnebacher, Michael Köhling, Rüdiger Kirschstein, Timo PLoS One Research Article Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary. While clinical guidelines recommend all approved anticonvulsants, so far it is still unclear which of the available drugs is the best therapeutic option for treating glioma-associated seizures, also in view of possible anti-tumorigenic effects. In our study, we employed four patient-derived low-passage cell lines of glioblastoma and three cell lines of brain metastases, and challenged these cultures with four anticonvulsants with different mechanisms of action: levetiracetam, valproic acid, carbamazepine and perampanel. Cell proliferation was determined by bromodeoxyuridine incorporation. To further analyze the effects of perampanel, apoptosis induction was measured by caspase 3/7 activation. Glutamate release was quantified and glucose uptake was determined using (18)F-fluorodeoxyglucose. Real-time polymerase chain reaction was employed to assess the expression of genes associated with glutamate release and uptake in brain tumor cells. Of the four anticonvulsants, only perampanel showed systematic inhibitory effects on cell proliferation, whereas all other anticonvulsants failed to inhibit glioma and metastasis cell growth in vitro. Metastasis cells were much more resistant to perampanel than glioblastoma cell lines. Glucose uptake was attenuated in all glioblastoma cells after perampanel exposure, whereas cell death via apoptosis was not induced. Extracellular glutamate levels were found to be significantly higher in glioblastoma cell lines as compared to metastasis cell lines, but could be reduced by perampanel exposure. Incubation with perampanel up-regulated glutamine synthetase expression in glioblastoma cells, whereas treatment with valproic acid and levetiracetam downregulated excitatory amino acid transporter-2 expression. Overall, our data suggest that perampanel acts as an anticonvulsive drug and additionally mediated anti-tumorigenic effects. Public Library of Science 2019-02-04 /pmc/articles/PMC6361447/ /pubmed/30716120 http://dx.doi.org/10.1371/journal.pone.0211644 Text en © 2019 Lange et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lange, Falko
Weßlau, Konrad
Porath, Katrin
Hörnschemeyer, Julia
Bergner, Carina
Krause, Bernd Joachim
Mullins, Christina Susanne
Linnebacher, Michael
Köhling, Rüdiger
Kirschstein, Timo
AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
title AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
title_full AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
title_fullStr AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
title_full_unstemmed AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
title_short AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
title_sort ampa receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361447/
https://www.ncbi.nlm.nih.gov/pubmed/30716120
http://dx.doi.org/10.1371/journal.pone.0211644
work_keys_str_mv AT langefalko ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT weßlaukonrad ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT porathkatrin ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT hornschemeyerjulia ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT bergnercarina ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT krauseberndjoachim ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT mullinschristinasusanne ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT linnebachermichael ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT kohlingrudiger ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro
AT kirschsteintimo ampareceptorantagonistperampanelaffectsglioblastomacellgrowthandglutamatereleaseinvitro